Measures to Reduce Mother-to-Child Transmission of Hepatitis B Virus in China: A Meta-Analysis
- 1k Downloads
Mother-to-child transmission (MTCT) is the main mode of spread of hepatitis B virus (HBV) in China. We performed a meta-analysis to compare the effects of three measures for prevention of MTCT.
A meta-analysis was performed on randomized controlled trials and non-randomized studies comparing the index of MTCT among five groups of pregnant women: hepatitis B immunoglobulin (HBIG) administration, antiviral treatment, placebo, elective caesarean section, and vaginal delivery.
Compared with the control group, the incidence of HBV intrauterine infection (RR = 0.42, 95 % CI 0.27–0.64, P < 0.0001) and the number of chronic hepatitis B (CHB) infants (RR = 0.44, 95 % CI 0.32–0.61, P < 0.00001) were lower in the HBIG administration group. In the antiviral treatment group, serum HBV DNA levels were lower (MD = −4.01, 95 % CI −5.07 to −2.94, P < 0.00001) at the time of delivery, and normalization of ALT levels was better (RR = 1.11, 95 % CI 1.06–1.17, P < 0.0001). Infant serum HBsAg positivity (RR = 0.45, 95 % CI 0.22–0.91, P = 0.03) and incidence of infant HBV transmission RR = 0.06, 95 % CI 0.01–0.24, P < 0.0001) were reduced in antiviral the treatment group. Infant serum anti-HBs positivity at birth (RR = 1.24, 95 % CI 0.89–1.74, P = 0.2) or at 6–7 months (RR = 0.98, 95 % CI 0.86–1.11, P = 0.73) was not significantly different between the caesarean section and vaginal delivery groups. The incidence of infant CHB infection may have been higher in the vaginal delivery group (RR = 2.20, 95 % CI 1.02–4.74, P = 0.04).
Administration of HBIG or antiviral therapy to HBV carrier mothers during pregnancy is effective in reducing MTCT.
KeywordsHepatitis B virus Mother-to-child transmission Reduce Meta-analysis
Zhi Zhou conceived the study, provided funding support, and revised the manuscript critically for important intellectual content. Hua Xu made substantial contributions to the design of the study and to acquisition, analysis, and interpretation of the data. Teng Zeng, Jun-Ying Liu, Yu Lei, Shan Zhong, Yun-Jian Sheng, and Hong Ren participated in the design of the study and in acquisition, analysis, and interpretation of data. All authors read and approved the final manuscript. This work was supported by National Nature Science Foundation of China (grant numbers 81171563 and 31000397).
Conflict of interest
- 21.Qiu YW, Jiang XH, Huang LH, et al. A study on the treatment of chronic hepatitis B with YMDD mutation. Chin J Hepatol. 2009;17:171–174.Google Scholar
- 28.Wang FY, Lin P, Zhang HZ. A randomized controlled trial on effect of hepatitis B immune globulin in preventing hepatitis B virus transmission from mothers to infants. Chin J Pediatr. 2008;46:61–63.Google Scholar
- 34.Zang L-J, Wang L. Blocking intrauterine infection by telbivudine in pregnant chronic hepatitis B patients. Chin J Hepatol. 2009;17:561–563.Google Scholar
- 35.Han G-R, Jiang H-X, Wang G-J, et al. Efficacy and safety of telbivudine in pregnant women to prevent perinatal transmission of hepatitis B virus. Chin J Hepatol. 2012;20:201–205.Google Scholar
- 36.Chen H, Ren J, Liu X-H. Influence of different delivery patterns on mother-to-child vertical transmission of HBV. Chin J Woman Child Health Res. 2008;19:214–216.Google Scholar
- 37.Huang L. Research about the efficacy of delivery mode on maternal-infant transmission of hepatitis B virus. New Med. 2012;43:247–249.Google Scholar
- 38.Fan W. Effect of delivery mode on maternal-infant transmission of hepatitis B Virus. Guangdong Med J. 2007;28:252–253.Google Scholar
- 39.Gu J. Effect of delivery mode on maternal-infant transmission of hepatitis B virus. Ningxia Med J. 2006;28:858–859.Google Scholar
- 40.Zhang Q. Effect of delivery mode on maternal-infant transmission of hepatitis B virus. Chin J Clin Med. 2009;16:570–571.Google Scholar
- 41.Zhang S. Effect of delivery and interruption mode on maternal-infant transmission of hepatitis B virus. Mod Prev Med. 2006;33:72–74.Google Scholar
- 42.Cai S. Discuss on relative factors of maternal-infant vertical transmission of hepatitis B virus. Mod Diagn Treat. 2009;20:23–24.Google Scholar
- 43.Liu H. Relevant research of delivery mode on maternal-infant transmission of hepatitis B virus. Chin J Mod Drug Appl. 2009;3:30–31.Google Scholar
- 45.Yue Y. Clinical study on the prevention of HBV from mother to infant by injection of HBIG in pregnant women with HBsAg. Chin J Pract Gynecol Obstet. 1999;15:547–548.Google Scholar
- 47.Han ZH, Zhong LH, Wang J, et al. The impact of antepartum injection of hepatitis B immunoglobulin on maternal serum HBV DNA and anti-HBs in the newborns. Chin J Internal Med. 2007;46:376–378.Google Scholar
- 49.Zhang RL, Luo Y, Xie JX, et al. A correlation analysis between the rate of vertical transmission of HBV and HBsAg-positive father to infant and the rate of neonatal cord blood HBV-DNA. Chin J Epidemiol. 2010;31:159–162.Google Scholar
- 52.Munderi P, Helen Wilkes H, Tumukunde D. Pregnancy rates and outcomes among women on triple-drug antiretroviral therapy in the DART trial [Poster WEPEB261]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa; 2009.Google Scholar